Candida auris: What to Know About the “Superbug” Fungus Making Headlines
If you have seen recent headlines about a dangerous “superbug” fungus spreading across the United States, you may be wondering whether you and your family should be concerned.
First, a quick clarification: the organism in the news is Candida auris (C. auris)—not Candida aureus. It is sometimes called a “superbug” because it can be resistant to multiple antifungal medications and can spread efficiently in healthcare settings.
The good news is that C. auris is primarily a problem for people who are already seriously ill or have significant healthcare exposures. Healthy people living in the community are generally at very low risk.
What is Candida auris?
Candida auris is a type of yeast (fungus). Unlike the common Candida species that can cause problems such as vaginal yeast infections or thrush, C. auris has several characteristics that make it particularly concerning to public health officials.
It can:
Cause serious, sometimes life-threatening infections
Be resistant to one or more classes of antifungal medications
Live on a person's skin without causing any symptoms
Persist on surfaces and medical equipment for long periods
Spread from person to person, particularly in healthcare environments
Be difficult to identify correctly using some traditional laboratory methods
The CDC reported 6,304 clinical cases in the United States in 2024, and cases have increased substantially since the organism was first identified in the United States in 2016. More recent 2026 surveillance shows that transmission continues in multiple states. Colorado has also reported cases.
This is a real public-health concern—but it is important to put the risk into perspective.
Who is most at risk?
C. auris generally does not cause illness in healthy people.
The people at greatest risk are those who are already medically vulnerable, particularly people who:
Have prolonged or frequent stays in hospitals or nursing facilities
Have spent time in intensive care
Have a weakened immune system
Have invasive medical devices such as central venous catheters, feeding tubes, or urinary catheters
Require mechanical ventilation
Have recently undergone major surgery or other invasive medical procedures
Have multiple serious underlying medical conditions
Have had previous healthcare exposure in a facility where C. auris is present
For example, an otherwise healthy person who goes to the doctor's office for a routine physical is not considered a high-risk person for C. auris infection.
The greatest concern is for patients who are already quite sick and spending substantial amounts of time in healthcare facilities.
Colonization is not the same thing as infection
One of the confusing aspects of C. auris is that a person can carry the fungus without actually being sick.
This is called colonization.
A colonized person may have C. auris living on their skin or other body sites without having any symptoms whatsoever. However, they can still spread the organism to surfaces, equipment, or other patients.
In some vulnerable patients, the fungus can eventually invade the body and cause a serious infection.
This distinction is important because colonization generally does not need antifungal treatment. Treatment is directed at people who have an actual clinical infection.
What are the symptoms?
There isn't a single set of symptoms that tells us someone has Candida auris.
The symptoms depend on where the infection occurs and can look very much like other infections.
Bloodstream infection
A bloodstream infection can cause:
Fever
Chills
Low blood pressure
Rapid heart rate
Generalized illness or weakness
A bloodstream infection can progress to sepsis and other life-threatening complications.
Wound infection
C. auris can infect wounds and other sites of broken skin. Symptoms may include redness, drainage, pain, swelling, or other signs of infection.
Ear infection
C. auris was originally identified from an ear infection, and it can still cause infections of the ear.
The important point is that symptoms alone cannot distinguish C. auris from more common bacterial or fungal infections. A laboratory test is required for identification.
How is Candida auris diagnosed?
Diagnosis can be surprisingly complicated.
A healthcare provider obtains a specimen from the site of suspected infection—for example, blood, a wound, or another appropriate body site—and sends it to a laboratory for identification.
The challenge is that some traditional laboratory methods can mistakenly identify C. auris as another type of yeast.
Accurate identification generally requires more specialized laboratory technology, such as mass spectrometry or genetic sequencing.
There is also a separate test used for people who may have been exposed to C. auris. This is called screening for colonization and typically involves swabbing the skin, particularly areas such as the armpits and groin.
Screening is particularly useful during healthcare-facility outbreaks because identifying colonized patients allows healthcare workers to take steps to prevent transmission.
Importantly, routine screening of healthy people in the community is not recommended.
How is Candida auris treated?
Treatment depends on whether the patient has an actual infection, how sick they are, and which antifungal medications the particular strain is susceptible to.
For adults with clinical C. auris infection, the CDC recommends an antifungal class called echinocandins as initial treatment. These include medications such as micafungin, anidulafungin, and caspofungin.
Unfortunately, resistance is an important problem.
Most C. auris isolates are resistant to at least one antifungal medication, and some strains are resistant to multiple classes. Recent CDC laboratory surveillance found particularly high rates of fluconazole resistance among tested U.S. isolates.
For this reason, antifungal susceptibility testing is recommended for clinical C. auris infections. If a strain is resistant to echinocandins or multiple antifungal classes, treatment becomes considerably more complicated and usually requires consultation with an infectious-disease specialist.
Older antifungal guidelines for invasive candidiasis also support echinocandins as initial therapy for candidemia, with alternative agents such as amphotericin B considered in certain resistant or refractory infections.
Does someone who has Candida auris need to be treated if they feel fine?
Usually, no.
This is one of the most important distinctions to understand.
Someone can test positive for C. auris because they are colonized, rather than infected. Colonization does not necessarily make someone sick, and antifungal treatment is not routinely recommended simply to eliminate colonization.
Unfortunately, there is currently no reliably effective strategy for completely removing C. auris from the skin of a colonized person. Instead, healthcare facilities focus on preventing transmission through hand hygiene, appropriate protective equipment, environmental cleaning, and communication between healthcare facilities.
How does it spread?
C. auris is particularly good at spreading in healthcare environments.
It can be transferred through contact with:
Hands
Bed rails
Medical equipment
Door handles
Other frequently touched surfaces
Unlike many organisms, C. auris can persist on surfaces for extended periods of time, which makes environmental cleaning particularly important.
Healthcare facilities therefore use specific infection-control measures when caring for patients known to be infected or colonized.
For patients returning home, CDC recommends good hand hygiene and communicating a previous C. auris diagnosis or positive screening test to future healthcare providers.
Should I be worried about getting Candida auris?
For most people, no.
If you are generally healthy and living in the community, your risk is very low. C. auris is not primarily a community-acquired infection like influenza, COVID-19, or a typical stomach virus.
The people we worry about most are those who are already very sick and have substantial healthcare exposure.
That said, if you or a family member has spent a prolonged period in a hospital, nursing facility, or intensive care unit—or has been told that you were exposed to C. auris—it is important to tell your healthcare providers.
And if you develop signs of a serious infection such as persistent fever, chills, confusion, weakness, or low blood pressure after a significant healthcare exposure, you should seek medical attention promptly.
What can you do to protect yourself?
There is no reason to disinfect your entire house or routinely test yourself for Candida auris.
Instead, focus on the basics:
Wash your hands. Good hand hygiene remains one of the most effective ways to prevent healthcare-associated infections.
Tell your healthcare team about previous C. auris exposure. If you have ever tested positive or been told you were exposed, let healthcare providers know before future healthcare visits or hospitalizations.
Ask questions when hospitalized. If you or a loved one is in a healthcare facility, don't hesitate to ask about hand hygiene and infection-control practices.
Don't take antifungal medication unnecessarily. Antifungal resistance is one of the reasons C. auris is concerning in the first place. Treatment should be directed at confirmed or strongly suspected clinical infection rather than used indiscriminately.
The bottom line
Candida auris deserves attention because it is difficult to identify, can spread efficiently in healthcare settings, and is frequently resistant to antifungal medications. But the current headlines can make the risk sound much greater to healthy people than it actually is.
For the average healthy person living in the community, C. auris is not something to be afraid of or routinely tested for.
For people who are seriously ill, immunocompromised, or spending significant amounts of time in hospitals or long-term care facilities, however, it is an important infection-control and medical concern.
At Homestead Direct Primary Care, we believe that understanding emerging infections without unnecessary fear is an important part of good medical care. If you have questions about Candida auris, a recent hospitalization, or an infection that isn't behaving as expected, we're happy to help you sort through what actually matters for your individual situation.
Sources and further reading
Centers for Disease Control and Prevention (CDC), Candida auris: background, symptoms, risk factors, prevention, surveillance, and clinical management.
CDC, Tracking C. auris — U.S. surveillance data.
Colorado Department of Public Health and Environment, Candida auris.
CDC Emerging Infectious Diseases, 2026 report on antifungal susceptibility of U.S. C. auris isolates.
Infectious Diseases Society of America, Clinical Practice Guideline for the Management of Candidiasis.
This article is for general educational purposes and is not a substitute for individualized medical advice.
